FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026: On April 30, 2026, the FDA published a proposal to permanently remove semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use in compounding — regardless of drug shortage status. Public comment on the proposal closes June 29, 2026. If finalized, no 503B pharmacy could legally bulk-compound any of these three GLP-1 drugs in the future, even if a new shortage is declared. This is a permanent structural change, not a temporary shortage-enforcement action.

• •What changed: FDA proposed permanent 503B exclusion for semaglutide, tirzepatide, and liraglutide on April 30, 2026
• •Comment period: Closes June 29, 2026 — submit via the Federal Register notice (the page has a 'Submit a Formal Comment' button that routes to the active regulations.gov docket).
• •Immediate patient impact: None — the proposal is not yet finalized. Current shortage-based bans remain in place unchanged.
• •If finalized: 503B outsourcing facilities permanently cannot bulk-compound these three drugs, even during a future shortage
• •What stays legal: 503A patient-specific compounding under narrow medical-necessity criteria (allergy to inactive ingredients, non-standard dose)
• •Compounded tirzepatide: Still legal now — tirzepatide shortage is active. Monitor FDA alerts for changes.

What the 503B Bulk List Is — and Why This Matters

503B outsourcing facilities are large-scale pharmaceutical manufacturers licensed by the FDA to compound drugs at commercial scale. Unlike 503A patient-specific pharmacies — which fill individual prescriptions one at a time — 503B facilities can produce bulk quantities for healthcare facilities and telehealth platforms. That production capacity is what powered the compounded GLP-1 boom from 2021 to 2025.

Under federal law, 503B facilities can compound drugs using ingredients from the FDA's 'nominated bulk drugs' list. The list exists to allow compounding when brand-name supply is short. When a drug is removed from the shortage list, compounders lose their legal basis to produce it at scale — but under the current rules, they could theoretically restart if a new shortage is declared. The permanent exclusion proposal closes that door permanently.

The FDA's stated rationale, per the Orrick regulatory analysis of the proposal: when manufacturers have proven they can maintain adequate supply, allowing large-scale 503B compounding of their products creates safety risks without the shortage benefit. Over 520 adverse event reports linked to compounded GLP-1 products — including contamination, dosing errors, and unapproved additives — are part of the agency's record supporting permanent exclusion.

How This Differs from the Current Semaglutide and Tirzepatide Enforcement

The current semaglutide crackdown and compounded tirzepatide rules are both shortage-dependent: they are enforced because FDA removed semaglutide from the shortage list in October 2024 and because tirzepatide remains on the shortage list, respectively. The new proposal operates on entirely different legal authority.

In practical terms: the current enforcement says 'you cannot compound semaglutide because the shortage is over.' The proposed permanent ban says 'even if semaglutide goes back on shortage in the future, 503B facilities still cannot bulk-compound it.' That removes any path back to the pre-2025 compounded GLP-1 market for large-scale outsourcing facilities.

Why Liraglutide Is Included in the Proposal

Liraglutide — the active ingredient in Victoza (type 2 diabetes) and Saxenda (weight loss) — is an older GLP-1 with no active shortage. Including it in the permanent exclusion proposal signals the FDA is closing a potential substitution loophole: as semaglutide and tirzepatide compounding access narrows, some 503B facilities could shift production to liraglutide, which shares GLP-1 mechanisms and is technically similar to compound at scale.

Liraglutide produces 5-6% body weight loss versus 15-21% for tirzepatide and 15% for semaglutide, so it was not the primary driver of the compounded GLP-1 market. But the FDA is not leaving that gap open. Including liraglutide now prevents a second enforcement cycle later.

What Remains Legal: Your 503A Patient-Specific Options

The permanent exclusion proposal applies exclusively to 503B outsourcing facilities. It does not change the rules for 503A patient-specific compounding pharmacies, which operate under a different section of the Federal Food, Drug, and Cosmetic Act. Under 503A, a licensed prescriber can still write a patient-specific prescription for compounded semaglutide, tirzepatide, or liraglutide if:

• •Documented allergy — The patient has a verified allergy to a specific inactive ingredient in the commercial product that is not present in the compounded formulation
• •Non-commercially-available dose — The patient requires a specific dose or concentration that is not available in any FDA-approved strength
• •Individual prescription required — The prescriber must document medical necessity for each individual patient; standing orders for patient populations do not qualify

How to Submit a Public Comment Before June 29

The public comment period on the proposal closes June 29, 2026. Patients, prescribers, pharmacists, telehealth companies, and patient advocacy organizations can all submit comments. The FDA reviews all substantive comments before issuing a final rule.

• •Where to comment: the Federal Register notice 2026-08552 — use the 'Submit a Formal Comment' button on that page, which routes to the active regulations.gov docket
• •What carries weight: Documented patient cases, clinical data, safety comparisons between 503B products and brand-name drugs, economic impact for patients who relied on compounded access
• •Who should comment: Patient advocacy groups, healthcare providers who prescribe compounded GLP-1s, pharmacy associations, and patients using legitimate medical-necessity exemptions
• •Deadline: June 29, 2026 — comments submitted after this date will not be considered in the final rule

What This Means for Your GLP-1 Access Right Now

The proposal is not yet finalized — the June 29 comment period and FDA review process mean any final rule is months away. Your immediate access is governed by the current rules, not the proposed permanent ban. Here is where things stand by drug:

If you are currently on compounded tirzepatide from a licensed 503B provider, you have time. The tirzepatide shortage remains active as of May 2026. But the direction of travel is clear: FDA is systematically closing large-scale GLP-1 compounding. Our top-rated compliant compounded tirzepatide providers — Enhance MD ($149/mo), Shed ($199/mo), and Sprout Health — all operate under verified pharmacy partnerships.

If you need to switch off compounded semaglutide, your best current paths are brand-name Wegovy ($349/mo via NovoCare), Zepbound from telehealth providers like Eden Health ($249/mo), or the newly approved oral option Foundayo (orforglipron) at $649/mo. For the complete switch guide, see compounded semaglutide: 4 legal alternatives.

Frequently Asked Questions

Does this proposal affect my current compounded tirzepatide prescription? Not immediately. Tirzepatide remains on the FDA drug shortage list as of May 2026, and the proposal is not yet finalized. Current 503B compounding of tirzepatide remains legal. Check our FDA safety alerts for real-time status.

Can my doctor still prescribe compounded semaglutide under 503A? Yes, under narrow medical-necessity criteria — documented allergy to inactive ingredients, or a required dose not available commercially. The 503B permanent exclusion proposal does not change 503A patient-specific rules.

Is there any scenario where 503B compounding of semaglutide could restart under the current rules? Yes — technically, if semaglutide went back on the FDA shortage list. That is exactly the loophole the permanent exclusion proposal is designed to close. If finalized, no future shortage declaration would reopen 503B compounding for these three drugs.

Why is liraglutide in the proposal if almost no one is using it for weight loss? The FDA is preventing a substitution market from forming. As semaglutide and tirzepatide 503B access closes, facilities could pivot to liraglutide compounding. Including it now avoids a second enforcement cycle.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical or legal advice. GLP-1 medications require a prescription from a licensed healthcare provider. Consult your prescriber before making any changes to your medication regimen. Regulatory status reflects information available as of May 8, 2026 and is subject to change.

Sources